P/B
3,4
Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
$20.3B
Market Cap • 9/11/2026
1998
(28 years)
Founded
2010
(16 years ago)
IPO
NASDAQ
Listing Exchange
Denmark
Country
Valuation
P/S
4,9
P/EBITDA
16,9
P/OCF
16,3
P/FCF
16,9
P/E
25,6
BVPS
9,6
EPS
1,3
Market Cap
Market Cap
20,3B
EV
24B
EV/Revenue
5,8
EV/EBITDA
20,1
EV/EBIT
22,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
2,6%
Total Yield
2,6%
Payout
0%
Retained Earnings
4,4B
Profitability
Gross Margin
93%
EBITDA Margin
29%
EBIT Margin
26%
Net Margin
21,6%
D&A/EBITDA
0%
R&D/Revenue
43,1%
Capex/Revenue
1,1%
Capex/D&A
34,9%
Capex/OCF
3,5%
SBC/OCF
17,3%
% PPE
2%
% Goodwill
2,8%
ROE
15,9%
ROIC
10,5%
Growth
CAGR Revenue 5Y
27,5%
CAGR Op. Income 5Y
15,3%
CAGR Net Income 5Y
15,8%
CAGR EPS 5Y
14,3%
CAGR OCF 5Y
4,9%
Leverage
N.D./EBITDA
3,1
Debt/Equity
0%
Current Ratio
2,5
Quick Ratio
2,4
Interest Coverage
252,8%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!